EL7.AI
StocksHigh Impact•31 March 2026•
1 min read

Biogen to Acquire Apellis Pharmaceuticals for $5.6 Billion; APLS Shares Surge 140%

Key Facts

1Biogen announced an agreement to acquire Apellis Pharmaceuticals in a deal valued at $5.6 billion.
2Apellis Pharmaceuticals (APLS) shares surged 140% in pre-market trading following the deal announcement.
3The acquisition aims to enhance Biogen's rare-disease treatment portfolio and accelerate its expansion into nephrology.

Biogen Inc. has announced a definitive agreement to acquire Apellis Pharmaceuticals in a landmark deal valued at approximately $5.6 billion. Following the announcement, shares of Apellis Pharmaceuticals (APLS) skyrocketed by 140% in pre-market trading as investors reacted to the premium valuation. This strategic acquisition is designed to significantly bolster Biogen's existing portfolio of rare-disease treatments. Furthermore, the deal is expected to accelerate Biogen's expansion into the high-growth field of nephrology. By integrating Apellis's innovative pipeline, Biogen aims to diversify its revenue streams and strengthen its long-term drug development strategy. This move underscores a major consolidation trend within the biotechnology sector as large players seek to acquire specialized clinical assets to drive future growth.